Shockwave Medical Inc (NASDAQ:SWAV) has been assigned a consensus broker rating score of 3.00 (Hold) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a hold rating.

Analysts have set a 1-year consensus price objective of $45.67 for the company and are anticipating that the company will post ($0.55) EPS for the current quarter, according to Zacks. Zacks has also given Shockwave Medical an industry rank of 95 out of 256 based on the ratings given to its competitors.

SWAV has been the subject of a number of recent research reports. Morgan Stanley initiated coverage on shares of Shockwave Medical in a research note on Monday, April 1st. They set an “equal weight” rating and a $32.00 price target for the company. Bank of America initiated coverage on shares of Shockwave Medical in a research note on Monday, April 1st. They set a “neutral” rating and a $37.00 price target for the company. Wells Fargo & Co initiated coverage on shares of Shockwave Medical in a research note on Monday, April 1st. They set a “market perform” rating and a $33.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Shockwave Medical from a “hold” rating to a “sell” rating in a research note on Friday, June 7th.

A number of large investors have recently modified their holdings of SWAV. FMR LLC acquired a new stake in shares of Shockwave Medical in the 1st quarter valued at $117,477,000. Gilder Gagnon Howe & Co. LLC acquired a new stake in shares of Shockwave Medical in the 1st quarter valued at $44,601,000. JPMorgan Chase & Co. acquired a new stake in shares of Shockwave Medical in the 1st quarter valued at $11,072,000. Redmile Group LLC acquired a new stake in shares of Shockwave Medical in the 1st quarter valued at $10,041,000. Finally, Morgan Stanley acquired a new stake in shares of Shockwave Medical in the 1st quarter valued at $7,768,000. 45.60% of the stock is owned by hedge funds and other institutional investors.

SWAV opened at $59.25 on Tuesday. The company has a quick ratio of 9.89, a current ratio of 10.37 and a debt-to-equity ratio of 0.11. Shockwave Medical has a fifty-two week low of $24.58 and a fifty-two week high of $68.39.

Shockwave Medical (NASDAQ:SWAV) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($1.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.85). The company had revenue of $7.27 million for the quarter. On average, equities analysts forecast that Shockwave Medical will post -2.74 EPS for the current fiscal year.

Shockwave Medical Company Profile

ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.

Further Reading: Technical Indicators – What is a Golden Cross?

Get a free copy of the Zacks research report on Shockwave Medical (SWAV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.